An updated guideline has been published by the AHA, ACC, and other organizations regarding the management of acute coronary syndrome.

Endologix LLC announced it has reached a milestone of 1,000 patients who have been treated with percutaneous transmural ...

Lifestyle and health factors that are linked with heart disease appear to have a greater impact on cardiovascular risk in ...

Poor performance on quality metrics carried greater risk of in-hospital mortality no matter where patients initially ...

The global coronary artery bypass graft market is projected to reach USD 18,700.6 million by 2025 and continue its upward trajectory with a CAGR of 2.9%, reaching approximately USD 24,887.3 million by ...

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today ...

Financial Results for the Fourth Quarter Ended December 31, 2024 For the fourth quarter of 2024, total revenue increased by $188,000, or 10.7%, to $1,949,000, from $1,761,000 during the fourth quarter ...

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.

The approval is only for the 2.5mg tablet. Xarelto is also available in 10mg, 15mg, and 20mg tablets, as well as an oral suspension (1mg/mL), to treat various conditions.

Medtronic (NYSE: MDT) announced results from a registry highlighting the effectiveness of the Prevail drug-coated balloon ...

Lupin announced that it has launched Rivaroxaban tablets USP, 2.5 mg, in the US market following final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug ...

Outcomes included all-cause mortality, myocardial infarction (MI), new revascularization with percutaneous coronary ...